Author

Dian Kortleve

Erasmus MCORCID 0000-0001-5192-4471Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Anita Trapman-JanseniD· 1 shared Chen‐Yi LiaoiD· 1 shared Daphne RoelofsiD· 1 shared Dora HammerliD· 1 shared Erik H.J. DaneniD· 1 shared Jeroen DemmersiD· 1 shared John W.M. MartensiD· 1 shared Justine MichauxiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Anita Trapman-JansenORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ImmunologyCancer DiscoveryPeer-reviewedAug 21, 2024

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models

Dian Kortleve, Dora Hammerl, Mandy van Brakel…·Reno Debets

This study identifies ROPN1 as a target for TCR-engineered T-cells effective against TNBC in preclinical models and demonstrates their safety and efficacy.

16 citations

humanproteomics

𝕏 PostBluesky